AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04816656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePROMs assessment
Description: At inclusion the patient received a unique login code which he/she used to start the care path. After signing the informed consent on the digital pathway, the patient needed to fill in the questionnaires that were presented at fixed time points throughout this study.~Based on the data collected from the questionnaires the patient received customized information and advice. In case of COVID-19, the information and advice was based on the guidelines from Sciensano and the Belgian government. If the patient suffered from side effects from the cancer therapy, they received tips and tricks how to manage these complications. The collected data was forwarded to the patient medical file. As such health care workers were be able to use this information in the patients' follow up consultations.
Study NCT02375841 — intervention group
Intervention type: BEHAVIORAL
Intervention: psychometric tests, questionnaires and neurocognitive assessments
Study NCT04301128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Patients in the experimental group were educated and followed with an android based mobile application which contains the informations related to the disease, treatment and its complications, monitoring and cure and provides side effect tracking.
Study NCT04301128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Patients in the control group were informed same informations verbally and given an education book.
Study NCT04270682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded CDCA 250 mg TID
Description: Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
Study NCT04270682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Adult cohort patients will receive blinded 250 mg CDCA TID or placebo during the double-blind periods based upon their treatment assignment.
Study NCT04270682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-Label CDCA 250 mg TID
Description: Adult cohort patients will receive open-label 250 mg CDCA TID during the run-in and washout periods of the study or as rescue medication during the double-blind periods, if needed, based on clinical symptoms.
Study NCT04270682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue Medication CDCA 250 mg TID
Description: CDCA 250 mg TID will be provided as rescue medication during the double-blind periods, if needed, based on laboratory results.
Study NCT04270682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDCA Weight-Based Dose TID
Description: Patients in the pediatric cohort will complete a weight-based dose titration to a tolerated dose and will maintain that tolerated dose for the remainder of the study. Pediatric cohort dosing of CDCA will not exceed an equivalent dose of 750 mg/day.
Study NCT00086359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir sulfate, lamivudine, and zidovudine
Description: one pill twice daily
Study NCT00086359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine/zidovudine
Description: one pill twice daily
Study NCT00086359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: four pills twice daily
Study NCT03699163 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breath sample
Description: Patients will be asked to give a sample of their breath, using the ReCIVA breath testing device. This involves performing tidal breathing whilst wearing a face mask for approximately 5 minutes. Breath (500mls at a flow rate of 200mls/min) is passed over thermal desorption tubes which absorb compounds of interest.
Study NCT03407144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 2 mg/kg intravenous (IV) up to a max of 200 mg (3 to 17 years of age) or 200 mg IV (18 to 25 years of age); cycle frequency Q3W
Study NCT03407144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 25 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~40 mg/m\^2 IV on Days 1 and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~25 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)
Study NCT03407144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: 6 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~6 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)
Study NCT03407144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: 375 mg/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~375 mg/m\^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)~250 mg/m\^2 IV on Days 1 to 3 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)
Study NCT03407144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 500 mg/m\^2 IV on days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)
Study NCT03368742 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SGT-001
Description: AAV9 vector containing muscle-specific promoter and microdystrophin construct
Study NCT03029182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking+simulated-altitude
Description: Participants will walk on a treadmill for up to 50 minutes at a 16% oxygen level (administered via exercise mask), which is similar in altitude to Flagstaff, AZ. The progression of exercise training will be based on a varying percents of heart rate reserve.
Study NCT03029182 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking (control)
Description: Participants will walk on a treadmill for up to 50 minutes.The progression of exercise training will be based on a varying percents of heart rate reserve.
Study NCT01741025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFuse Implant System
Description: Placement of iFuse implant system via surgery
Study NCT01741025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Management
Description: Medications for pain, physical therapy, cognitive behavour therapy
Study NCT03325868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate
Description: Ulipristal 5mg daily by mouth for 12 weeks
Study NCT00868140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: pioglitazone 45 mg
Study NCT00868140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo daily
Study NCT02621151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02621151 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of Bladder Tumor
Study NCT02621151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02621151 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Study NCT04200755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab 300Mg Solution for Injection
Description: First dose: 600 mg (2 syringes); subsequent doses: 300 mg (1 syringe)
Study NCT04200755 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: First dose: 2 syringes, no active substance; subsequent doses: 1 syringe, no active substance
Study NCT01712997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Study NCT01712997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Study NCT01712997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan
Study NCT04426149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: trehalose
Description: patients were instructed to ingest 100g of oral trehalose diluted in 500ml of water or other beverages daily
Study NCT03415451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiberscope-Guided Nasogastric tube insertion
Description: Fiberscope-Guided Nasogastric tube insertion
Study NCT00090233 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotateq™
Description: 3 doses of 2.0 mL RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
Study NCT00090233 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: 3 doses of 2.0 mL Placebo to RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
Study NCT02865954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iball (mhealth application)
Description: mhealth application and associated device to support activation of the pelvic floor muscles.
Study NCT03407144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 1.5 mg/m\^2 IV with maximum single dose 2 mg on Days 1, 8, and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~1.5 mg/m\^2 IV with maximum single dose 2 mg on Days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)
Study NCT01805908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 111In-Pertuzumab + SPECT-CT
Description: 111In-PmAb will be provided ready for injection in a vial by Dr. Reilly's laboratory.
Study NCT02566785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Intervention
Description: The multi-component balance intervention will be 1x per week in supervised group sessions and 2x a week sessions at home. Sessions will begin with a 5 minute warm up of major muscle groups using flexibility exercises and end with a cool down. Sessions will focus on improving static balance in the initial stages, then progress to dynamic balance.
Study NCT02566785 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Balance Intervention
Description: The multi-component balance intervention will be 1x per week in supervised group sessions and 2x a week sessions at home. Sessions will begin with a 5 minute warm up of major muscle groups using flexibility exercises and end with a cool down. Sessions will focus on improving static balance in the initial stages, then progress to dynamic balance.
Study NCT01394692 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraoperative MRI-guided tumor resection
Description: tumor resection with the use of an intraoperative MRI
Study NCT01394692 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard microsurgery
Description: microsurgical tumor resection
Study NCT01049230 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam radiation
Description: Once a day, 5 days a week (Monday-Friday), for 4-8 weeks
Study NCT01252186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 91-day Levonorgestrel Oral Contraceptive
Description: 91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
Study NCT01252186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 28-day Levonorgestrel Oral Contraceptive
Description: 21 combination tablets containing 150 µg LNG/30 µg EE.
Study NCT01252186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 28-day Desogestrel Oral Contraceptive
Description: 21 combination tablets containing 150 µg DSG/30 µg EE.
Study NCT01510366 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Sabin strains)
Description: Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections, one month apart.
Study NCT01510366 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Salk strains)
Description: Inactivated Poliomyelitis Vaccine (Salk strains)3 x 0.5ml intramuscular injections, one month apart.
Study NCT02407340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: 40 international Units (IU) 3xday delivered as 5 sprays (0.1 mL) per nostril
Study NCT02407340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 5 sprays (0.1 mL) per nostril 3xday; bottles are identical to those of active drug
Study NCT04074694 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sialoendoscopy
Description: Sialoendoscopy
Study NCT02533986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berry peel drink
Study NCT02533986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control drink
Study NCT03117374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team Nutriathlon intervention
Description: 8 wk web-based nutrition intervention program aimed at increasing the consumption of fruits, vegetables and dairy products.
Study NCT00500058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-485232
Description: SB-485232 for injection, 7 mg/vial, will be available as a lyophilized cake. It will be reconstituted with 1.4 mL of water for injection. Each vial of this drug product is a clear, colorless solution containing 5 mg/mL of SB-485232.
Study NCT00500058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 will be administered by IV infusion.
Study NCT03475706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solabegron immediate release tablets, low dose
Description: twice daily for 12 weeks.
Study NCT03475706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solabegron immediate release tablets, high dose
Description: twice daily for 12 weeks.
Study NCT03475706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: twice daily for 12 weeks.
Study NCT03630991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edetate Calcium Disodium
Description: Given IV
Study NCT03630991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin
Description: Given PO
Study NCT03630991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succimer
Description: Given PO
Study NCT04219553 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comparator (no intervention)
Description: No active intervention
Study NCT03598985 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Smartphone MyAnkle balance application
Description: Balance will be assessed simultaneously using MyAnkle application and the Biodex balance system. The smartphone will be fixed to the middle of the shin with an armband. Participants will assume a single leg stance on each side under two conditions: eyes opened and closed. Testing will be done at three levels of difficulty; least difficult (level 8), moderate (level 6) and severe difficult (level 4). A conditioning trial for each level will be given for 30 seconds. Further, a 2-minute rest between tests will be given. During the testing, participants should not touch the ground or stance limb by other limb nor to grasp the handrail. Participants will repeat the same testing in two separate sessions, with one-week interval in between.
Study NCT02305017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 50 mg
Study NCT03671967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Description: 4.5 grams QID
Study NCT03671967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: 1 gram TID
Study NCT02305017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol 1g
Study NCT02302092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flomoxef
Description: Flomoxef intravenous infusion
Study NCT02302092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefepime
Description: Cefepime intravenous infusion
Study NCT06657092 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Single-shot ultrasound (US)-guided ESP block with 20 ml 0.25% bupivacaine ( Marcaine ) at the T4 vertebral level will be performed.
Study NCT06657092 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standart therapy
Description: Postoperative 0.5 mg/kg morphine and 1 gr paracetamol will be admistered intravenously in the operation theatre and intravenous patient controlled analgesia (PCA) will be performed in the plastic surgery ward postoperatively
Study NCT03296137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous tumor-infiltrating lymphocytes
Description: Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion.
Study NCT03296137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: One treatment with ipilimumab (3 mg/kg) prior to tumor resection.
Study NCT03296137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 4 doses of nivolumab. Starting 2 days prior to TIL infusion and every 2 weeks hereafter.
Study NCT03296137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: proleukin
Description: 2 MIE s.c. injection, after TIL infusion and continuing for 2 weeks
Study NCT03296137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2 doses (60 mg/kg) prior to TIL infusion
Study NCT03296137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludara
Description: 5 doses (25 mg/m2) prior to TIL infusion
Study NCT02103361 — intervention group
Intervention type: DRUG
Intervention: Ustekinumab
Study NCT02103361 — intervention group
Intervention type: DRUG
Intervention: Guselkumab
Study NCT05119491 — intervention group
Intervention type: DEVICE
Intervention: uitrasonography and spirometry
Description: chest uitrasonography and spirometry
Study NCT02659930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: liposomal doxorubicin IV day 1 of a 28-day cycle
Study NCT02659930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: pomalidomide once a day, days 1-21 of a 28-day cycle, at the dose levels described in dose escalation plan
Study NCT04164199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously.
Study NCT04164199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Administered orally.
Study NCT04164199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Administered orally.
Study NCT04164199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Administered orally.
Study NCT04164199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Administered intravenously.
Study NCT04164199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1706
Description: Administered intravenously.
Study NCT04164199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Administered orally.
Study NCT04164199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-15025
Description: Administered orally.
Study NCT04164199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Administered intravenously.
Study NCT04164199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: Administered intravenously.
Study NCT04164199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surzebiclimab
Description: Administered intravenously.
Study NCT04164199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered orally.
Study NCT04164199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-007
Description: Administered intravenously.
Study NCT03407144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone/prednisolone
Description: 60 mg/m\^2/day orally divided in 3 doses on Days 1 to 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~40 mg/m\^2/day orally divided in 3 doses on Days 1 to 15 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)
Study NCT03407144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bleomycin
Description: 10 units/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)
Study NCT03407144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 125 mg/m\^2 IV on Days 1 to 5 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)
Study NCT03407144 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Description: RT administered daily, dose dependent on randomization group and disease response.
Study NCT04456413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Fresh or frozen plasma will be infused one time to hospitalized patients with COVID-19 infection
Study NCT04456413 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: Patients will receive best supportive care. Patients randomized to this arm may receive plasma should they require hospitalization for progression of COVID-19 disease.